|Trade names||Arranon, Atriance|
|Main uses||Acute T-cell lymphoblastic leukemia and lymphoma|
|Side effects||Bone marrow suppression, sleepiness, headache, numbness, fever, swelling, vomiting|
|Metabolism||By adenosine deaminase, to 9-β-D-arabinofuranosylguanine|
|Elimination half-life||30 minutes (nelarabine)|
3 hours (ara-G)
|Chemical and physical data|
|Molar mass||297.271 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Nelarabine, sold under the brand names Arranon and Atriance , is a medication used to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It is used when other treatments are not effective. It is given by gradual injection into a vein.
Common side effects include bone marrow suppression, sleepiness, headache, numbness, fever, swelling, and vomiting. Other side effects may include confusion, seizures, tumor lysis syndrome, and peripheral neuropathy. Use in pregnancy may harm the baby. It is an antimetabolite which replaces guanine and interferes with the making of new DNA.
Nelarabine was approved for medical use in the United States and Europe in 2005. In the United Kingdom six vials of 250 mg cost the NHS about £1,300 as of 2021. In the United States this amount costs about 4,600 USD.
In adults it is used at a dose of 1500 mg/m2 on day 1, 3, and 5 out of 21 days.
- "Atriance". Retrieved 12 November 2021.
- "Nelarabine Monograph for Professionals". Drugs.com. Retrieved 12 November 2021.
- "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.
- "Atriance EPAR". European Medicines Agency (EMA). Retrieved 4 December 2020.
- "DailyMed - ARRANON- nelarabine injection". dailymed.nlm.nih.gov. Retrieved 12 November 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 960. ISBN 978-0857114105.
- "Arranon Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 November 2021.